(-0.26%) 4 538.85 points
(0.65%) 35 660 points
(-0.81%) 14 143 points
(0.63%) $2 059.90
Live Chart Being Loaded With Signals
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease...
|Today's Volume||756 351|
|EPS||$0 ( 2023-11-01 )|
|Last Dividend||$0 ( N/A )|
|Next Dividend||$0 ( N/A )|
|2023-10-27||Cloghessy Paula||Buy||9 418||Common Stock|
|2023-10-30||Cloghessy Paula||Sell||2 904||Common Stock|
|2023-04-27||Cloghessy Paula||Buy||18 835||Restricted Stock Units|
|2023-10-27||Cloghessy Paula||Sell||9 418||Restricted Stock Units|
|2023-10-27||Shaff Eric D.||Buy||27 838||Common Stock|
|Last 96 transactions|
|Buy: 7 491 099 | Sell: 164 875|
Seres Therapeutics Inc Correlation
|10 Most Positive Correlations|
|10 Most Negative Correlations|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Seres Therapeutics Inc Correlation - Currency/Commodity
Seres Therapeutics Inc Financials
|Gross Profit:||$6.12M (85.91 %)|
|Gross Profit:||$-209 000 (-67.42 %)|
|Gross Profit:||$124.37M (98.33 %)|
|Gross Profit:||$-4.13M (791.00 %)|
Seres Therapeutics Inc
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.